 "Nifty outlook & trading ideas by HDFC Sec: Buy Bajaj Finance, Dr Reddy's")
Nifty outlook
Nifty made an attempt to surpass the crucial resistance of 15,915, but failed to do so. The index found resistance at 15,914 and ended with long-legged “Doji” candle on July 6, 2021. In the last one month, this was the third attempt by Nifty to surpass 15,900. However, the trend would be considered bullish unless Nifty breaks below its 20-day EMA, placed at 15,700-odd levels. On the upside, If 15,900 is taken out decisively; we can expect Nifty to reach 16,200 target immediately. Nifty Smallcap Index closed with bearish engulfing candlestick pattern on the daily chart. This could result in further profit booking in small caps.
Nifty made an attempt to surpass the crucial resistance of 15,915, but failed to do so. The index found resistance at 15,914 and ended with long-legged “Doji” candle on July 6, 2021. In the last one month, this was the third attempt by Nifty to surpass 15,900. However, the trend would be considered bullish unless Nifty breaks below its 20-day EMA, placed at 15,700-odd levels. On the upside, If 15,900 is taken out decisively; we can expect Nifty to reach 16,200 target immediately. Nifty Smallcap Index closed with bearish engulfing candlestick pattern on the daily chart. This could result in further profit booking in small caps.
Recommendations
Buy BAJAJ FINANCE (Rs 6,205): | Target: Rs. 6,500 | Stop-loss: Rs 6,000
The stock price has broken out from symmetrical triangle on the daily charts. Rising volumes have confirmed the breakout. Primary trend of the stock has been bullish as the stock has been forming higher tops and higher bottoms on the daily and weekly charts. The stock is placed above medium to long term moving averages, indicating bullish trend on all time frames. Indicators and oscillators on weekly and monthly charts have turned bullish
Buy DR REDDY (Rs 5,544): | Target Rs. 5,750 | Stop-loss: Rs 5,400
On the week ended July 2, 2021, the stock broke out from the previous top resistance by registering new all-time high with rising volumes. The stock has taken out the crucial resistance of 5,515, which was acting as a hurdle for the last four quarters. Pharma sector has been in an uptrend for many months now and this is expected to continue. Indicators and oscillators on daily and weekly charts have turned bullish. Besides, the stock has been finding support near its 20 day-EMA support.
Disclaimer: Vinay Rajani is a Senior Technical and Derivative Research Analyst at HDFC Securities. The analyst doesn't have any holding in the stock. Views are personal
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%